Home > Result Summaries: Compounds > Meningococcal Serogroups A, C, W-135 and Y Vaccine

Result Summaries: Meningococcal Serogroups A, C, W-135 and Y Vaccine

GSK Study ID	Phase	Title	Summary (Download)
102394	Phase 4	A Phase IV, partially double-blind study to demonstrate non-inferiority of GSK Biologicals’ Mencevax™ ACWY (new process) versus Mencevax™ ACWY (current process) when administered as a single dose to subjects aged 2-30 yrs (0 citation(s))
104171 & 104730	Phase 3	Pooled safety study of MenACWY vaccine given in subjects primed and boosted with investigational vaccination regimens and in subjects who received 4 doses of DTPw-HBV/Hib vaccine. (0 citation(s))
104730	Phase 3	A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax™ ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727. (0 citation(s))
104756	phase 3	Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007 (0 citation(s))
134612/003, 102252, 102253, 102254	Phase 2	A phase II open, primary vaccination study to assess the safety, reactogenicity, immunogenicity and long-term persistence of an investigational vaccination regimen versus one subcutaneous dose of Mencevax™ ACWY in healthy adults aged 18-25 years (1 citation(s))
208144/001	Phase 3	A phase III, open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Mencevax™ ACW135Y vaccine when administered as a single dose to healthy subjects aged 2-30 years.Mencevax™ ACW135Y: GSK Biologicals’ meningococcal serogroups ACWY vaccine (MenACWY) (0 citation(s))
208144/002	phase 4	Multicentric, Surveillance Study to Monitor Safety of GSK Biologicals' Purified Meningococcal Polysaccharide Vaccine of Serogroups ACWY in 3,000 Filipino Subjects Aged > 2 Yrs When Administered According to the Prescribing Information. (0 citation(s))
404286/006	Phase 2	A phase II, open, randomized, controlled study to assess the immune memory induced by an investigational vaccination regimen and the safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen in toddlers primed in study 404286/001. (0 citation(s))
675187/001	Phase 2	A Phase II, open, randomized, controlled study to evaluate the reactogenicity and safety of an investigational vaccination regimen in healthy toddlers aged 24-30 months. (0 citation(s))
711202/008	Phase 2	Evaluate the persistence and immune memory induced by a primary vaccination course with GSK Biologicals’ MenC-TT (1 formulation) & GSK Biologicals’ Hib-MenC-TT (2 formulations) or Meningitec™ in healthy toddlers aged 12-15 mths primed in study 711202/001 (1 citation(s))